Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia

Journal of Internal Medicine

Volumn 254, Issue 1, 2003, Pages 67-75

  Clarke, Robert ^a   Harrison, Georgina ^b   Richards, Sue ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Aspirin; Dementia; Homocysteine; Platelet function; Vitamins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; ISOPROSTANE; REACTIVE OXYGEN METABOLITE; THROMBOXANE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ASPIRIN; COGNITION DISORDERS; DEMENTIA; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; ISOPROSTANES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RIBOFLAVIN; THROMBOXANES; VITAMIN B 12; VITAMINS;

EID: 0038009864     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01154.x     Document Type: Article

References (31)

1. Hofman A, Ott A, Breteler MMB et al. Atherosclerosis, apolipoprotein E. and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
2. The Neuropathological Group of the Medical Research Council Cognitive Function and Ageing Study (CFAS). Pathological correlates of late-onset dementia in a multi-centre, community-based population in England and Wales. Lancet 2001; 357: 169-75.
3. Snowden DA, Greiner LH, Mortimer KP, Riley KP, Markesbery WR. Brain infarction and clinical expression of Alzheimer's disease: the Nun study. JAMA 1997; 277: 813-7.
4. Nagy Z, Esiri MM, Jobst KA et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathy Exp Neurol 1997; 56: 105-70.
5. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 1998; 55: 1449-55.
6. Antithrombotic Trialist's Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 234: 71-86.
7. Seshadri S, Beiser A, Selhub J et al. Plasma total homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
8. Budge M, Johnston C, Hogervast E et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000; 903: 407-10.
9. Vermeer SE, van Dijk EJ, Koudstaal PJ et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan study. Ann Neurol 2002; 51: 285-9.
10. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002; 59: 787-93.
11. Homocysteine Lowering Trialist's Collaboration. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998; 316: 894-8.
12. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-55.
13. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997; 23: 137-47.
14. 2-isoprostane in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 1777-83.
15. 2-isoprostane concentration in probable AD. Neurology 1999; 52: 562-5.
16. Engelhart MJ, Geerlings MI, Ruitenberg A, Hofman A, Witteman JCM, Breteler MMB. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 2002; 287: 3223-9.
17. In'T Veld BA, Ruitenberg AG, Hofman A et al. Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. NEJM 2001; 345: 1515-21.
18. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading cognitive state of patients for the clinician. J Psychiatr Res 1975; 313: 1419-20.
19. Prince M, MacDonald AM, Sham PC, Richards M, Quraishi S, Horn I. The development and validation of a telephone-administered cognitive test battery (TACT). Int J Meth Psych Res 1999; 8: 49-57.
20. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA, 1994.
21. Bucks RS, Ashworth D, Wilcock GK, Siegfried K, Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living scale. Age Ageing 1996; 25: 113-20.
22. Nexo E, Engbaek F, Ueland PM et al. Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine. Clin Chem 2000; 46: 1150-6.
23. Nexo E, Gimsing P. Insolubilized pure human intrinsic factor used for quantitation of cobalamin in serum. Scand J Lab Invest 1981; 41: 465-8.
24. Molloy AM, Scott JM. Microbiological assay for serum, plasma and red-cell folate using cryopreserved, microtiter plate method. Meth Enzymol 1997; 281: 43-53.
25. 2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative ion-chemical ionization mass spectrometry. Anal Biochem 1985; 150: 463-70.
26. 2 alpha. J Biol Chem 1995; 270: 9800-8.
27. 2 but not of systemic prostacyclin by controlled-release aspirin. NEJM 1991; 325: 1137-41.
28. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Sys-Eur) trial. Lancet 1998; 352: 1347-51.
29. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study randomised trial of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.